Eidos Therapeutics

Life Sciences
Written By Guest User
 

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.

  • Executive Medical Director

Guest User
Previous

Earli
Next

Eikon Therapeutics